Clinical trial
Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
NCT00227032 · UNC Lineberger Comprehensive Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00227032 |
|---|---|
| Title | Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme |
| Official title | Phase I Study of Erlotinib Administered Every 72 Hours in Patients With Glioblastoma Multiforme With Pharmacokinetic/Pharmacodynamic Correlates |
| Lead sponsor | UNC Lineberger Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | erlotinib hydrochloride |
| Enrollment | 10 |
| Start date | Sep 1, 2005 |
| Primary completion | Feb 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Sep 27, 2005 |
| Last update posted | Mar 6, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: